Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P20963

UPID:
CD3Z_HUMAN

ALTERNATIVE NAMES:
T-cell receptor T3 zeta chain

ALTERNATIVE UPACC:
P20963; B1AK49; Q5VX13; Q8TAX4

BACKGROUND:
Participating in adaptive immune response, the T-cell surface glycoprotein CD3 zeta chain is a component of the TCR-CD3 complex on T-lymphocytes. It is pivotal in transmitting signals from the cell surface to the interior upon antigen recognition, involving phosphorylation processes that activate downstream signaling pathways essential for T-cell activation and differentiation. This protein also contributes to the development of the nervous system's synaptic connections.

THERAPEUTIC SIGNIFICANCE:
Given its association with Immunodeficiency 25, exploring the T-cell surface glycoprotein CD3 zeta chain's function offers a promising avenue for developing targeted therapies to enhance immune system responses.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.